GSK CEO Emma Walmsley Files Initial Shareholding Notification
Ticker: GLAXF · Form: 6-K · Filed: Dec 12, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Dec 12, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-filing, shareholding, executive-disclosure
TL;DR
GSK CEO Walmsley filed an initial shareholding notice. Nothing to see here yet.
AI Summary
On December 12, 2024, GSK plc filed a Form 6-K reporting a transaction notification from Emma Walmsley, the Chief Executive Officer. This filing is an initial notification regarding shareholding.
Why It Matters
This filing provides transparency into the shareholding activities of key company executives, which can be an indicator of insider confidence.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of executive shareholding and does not indicate any immediate financial or operational risks for the company.
Key Players & Entities
- GSK plc (company) — Registrant
- Emma Walmsley (person) — Chief Executive Officer
- 001-15170 (dollar_amount) — Commission File Number
FAQ
What type of transaction is being reported by Emma Walmsley?
The filing is an initial notification regarding PDMR/person closely associated with them ('PCA') shareholding.
Who is the PDMR involved in this filing?
The PDMR is Emma Walmsley, the Chief Executive Officer of GSK plc.
What is the filing date of this report?
The filing date is December 12, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Does GSK plc file annual reports under Form 20-F?
Yes, GSK plc indicates it files or will file annual reports under cover of Form 20-F.
Filing Stats: 1,824 words · 7 min read · ~6 pages · Grade level 14.8 · Accepted 2024-12-12 11:12:09
Filing Documents
- a8992p.htm (6-K) — 202KB
- 0001654954-24-015446.txt ( ) — 203KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: December 12, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc